1Schluterman KO, Fassas AB, Van Hemert RL, et at. Multiple myeloma invasion of the central nervous system.Arch Neural, 2004, 61: 1423- 1429.
2Fassas AB, Ward S, Muwalla F, et at. Myeloma of the central nervous system:strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma, 2004, 45:291- 300.
5Faseas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol, 2002, 117: 103-108.
7Petersen SL, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation, a case report and review of the literature. Am J Hematol, 1999, 62: 228-233.
8Patriarca F, Prosdocimo S, Tomadini V, et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica, 2005, 90: 278-279.
9Luduis H, Khayat D, Giaccone G, et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer, 2005, 104: 1794-1807.
10Hattori Y, Iguchi T. Thalidomide for the treatment of multiple myeloma. Congenit Anom(kyoto), 2004, 44: 125-136,.
二级参考文献38
1Patriarca F, Zaja F, Silvestri F, et al. Meningeal and cerebral involvement in muhiple myeloma patients[J]. Ann Hematol, 2001, 80(12): 758-762.
2Schluterman KO, Fassas AB, Van Hemert RL, et al. Multiple myeloma invasion of the central nervous system [J]. Arch Neurol, 2004, 61(9): 1423-1429.
3Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis [J]. Cancer Treat Rev, 1999, 25(2): 103-119.
4Fassas A, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high -risk chromosomal abnormalities, plasmablastic morphology, and extramedullary manifestations[J]. Br J Haematol, 2002, 117(1): 103-108.
5Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor risk multiple myeloma after allotransplantation using a nonmyeloahlative conditioning regimen and donor lymphocyte infusions[J]. Blood, 2001, 970): 2574-2579.
6Fassas A, Ward S, Muwalla F, et al. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features[J]. Leukemia & Lymphoma, 2004, 45(2): 291-300.
7Roddie R, Collie D, Johnson P. Myelomatous involvement of the dura mater:a rare complication of muhiple myeloma [J]. J Clin Pathol, 2000, 53(5): 398-399.
8Dahl IM, Rasmussen T, Kauric G, et al. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma[J]. Br J Haematol, 2002, 116(2): 273-277.
9Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56 negative muhiple myeloma[J]. Br J Haematol, 2002, 117(4): 882-885.
10Mele G, Pinna S, Alloro E, et al. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma[J]. Leuk Res, 2007, 31(5): 721-723.
2BenyaEC, Goldman S. Bone marrow transplantation in children:imaging assessment of complications [J]. Pediatr Clin North Am,1997, 44(3): 741-761.
3CurtisRE, Rowlings PA, Deeg HJ, et al. Solid cancers afterbone marrow transplantation [J]. N Engl J Med, 1997, 336(13):897-904.
4SullivanKM, Mori M, Sanders J, et al. Late complications of al-logeneic and autologous marrow transplantation [J]. Bone MarrowTransplant, 1992, 10(Suppl 1): 127-134.
5ChenCY, Zimmerman RA, Faro S, et al. Childhood leukemia:central nervous system abnormalities during and after treatment[J].AJNR, 1996, 17(2): 295-310.
